What the TSA Shutdown Can Teach Biotech About Supply Chain Fragility

If you've traveled through a U.S. airport in the past few weeks, you already know the story. The partial government shutdown has left TSA officers working without pay — again — and the consequences are playing out in real time. Hundreds of agents have quit. Callout rates have more than doubled. Security lines at major hubs like Atlanta, Houston, and New York are stretching three, four, even five hours long. Spring break travelers are missing flights. Airports are warning passengers to arrive half a day early. The system, quite literally, is buckling under the weight of a single destabilized node.

I experienced it firsthand this month. And while I was standing in one of those lines, watching the frustration ripple through a terminal full of people who had no control over the situation, I couldn't stop thinking about something else entirely: biotech supply chains.

Because what's happening at our airports right now is a near-perfect analogy for what happens when a critical partner in your pharmaceutical supply chain — a contract manufacturer, a testing lab, a packaging and labeling provider, a logistics partner — becomes destabilized. And the lessons are the same.

One Weak Link. System-Wide Impact.

The TSA doesn't build planes. It doesn't sell tickets or manage air traffic. It performs one function in a complex system — screening passengers. But when that single function degrades, the entire system grinds to a halt. Airlines can't board on time. Connections are missed. Downstream schedules collapse. The ripple effects are massive and immediate, all because one node couldn't perform.

In biotech manufacturing, the parallels are striking. Your CMO might be one organization among many in your supply chain, but if they can't release batches on time, your clinical trial enrollment stalls. If your testing lab is backlogged, your commercial product sits in quarantine. If your packaging and labeling partner misses a deadline, your launch timeline shifts. Every node matters — and every node is a potential single point of failure.

The Problem Didn't Start the Day It Became Visible

Here's something worth noting about the TSA situation: the staffing crisis didn't begin when the lines hit three hours. It started weeks earlier, when officers began missing partial paychecks and morale started to erode. The resignations and callouts built gradually. By the time travelers felt the impact, the damage was already deep.

This is exactly how supply chain failures unfold in biotech. A CMO starts losing experienced operators. Deviation rates creep up. Response times on investigations slow down. Communication becomes less proactive. These are early warning signs — but too often, sponsors don't recognize them until a batch fails, a shipment is delayed, or a regulatory filing is at risk. By then, you're not preventing a problem. You're in crisis management mode.

Redundancy Isn't a Luxury — It's a Strategy

One of the most striking aspects of the airport chaos is how few alternatives travelers have. TSA is the only path through security. There's no backup. No second option. When it fails, you wait — or you don't fly.

Too many biotech companies operate their supply chains the same way. A single CMO for a critical product. One qualified testing lab. One logistics provider for temperature-sensitive shipments. When that sole-source partner stumbles, there's no Plan B — just scrambling.

Building redundancy into your supply chain isn't cheap, and it's not simple. Qualifying a second CMO or backup testing lab takes time, investment, and regulatory planning. But the cost of not having alternatives is almost always higher. A missed commercial launch window or a disrupted clinical supply doesn't just cost money — it costs time you can't get back, and in some cases, it costs patients access to therapies they need.

Relationships Under Stress Reveal the Truth

Disruption has a way of showing you who your real partners are. During the shutdown, some airports have communicated proactively, updated wait times in real time, and worked creatively with airlines to minimize passenger impact. Others have gone quiet, leaving travelers to figure it out on their own.

The same dynamic plays out with supply chain partners. When things go wrong — and they will — the partners who communicate early, take ownership, and collaborate on solutions are the ones worth keeping. The ones who go dark, deflect, or wait for you to discover the problem? That tells you everything you need to know about the long-term viability of that relationship.

If you haven't stress-tested your CMO and supplier relationships, you don't actually know how strong they are. Disruption will test them for you — usually at the worst possible time.

Governance Is What Keeps the System Running

At its core, the TSA crisis is a governance failure. Not a failure of the officers on the ground, who are largely showing up and doing their jobs under impossible conditions. It's a failure of the system above them — the funding mechanisms, contingency plans, and political structures that are supposed to keep critical operations running regardless of external circumstances.

In biotech supply chains, governance plays the same role. Joint steering committees, defined escalation pathways, shared KPIs, regular quality reviews — these aren't bureaucratic overhead. They're the infrastructure that keeps your supply chain functioning when individual nodes come under pressure. Without strong governance, small disruptions compound into large ones, and large ones become existential.

What You Can Do Right Now

You don't need to wait for your own supply chain "shutdown moment" to act. If the TSA headlines are making you uncomfortable, good — channel that into a hard look at your current operation. Ask yourself whether you have real-time visibility into your critical partners' health and capacity. Consider whether you've identified and documented your single points of failure. Evaluate how quickly you could activate an alternative if a key partner went down tomorrow. And think honestly about when you last stress-tested your governance structures — not on paper, but in practice.

The biotech companies that navigate disruption well aren't the ones with the most complex supply chains. They're the ones who've done the work before the disruption hits — building redundancy, investing in relationships, and putting governance in place that holds up under pressure.

The TSA lines will eventually get shorter. Funding will be restored. Agents will come back. But the vulnerability that the shutdown exposed? That's structural. And if you're running a biotech supply chain with the same kind of single-point-of-failure risk, the question isn't whether you'll face your own version of this crisis. It's when.

Verant Consulting Group helps biotech companies build resilient manufacturing and supply chain operations — before disruption forces the conversation. If you're not sure where your vulnerabilities are, let's find out together.